HCA Healthcare price target raised to $390 from $375 at Truist

Truist raised the firm’s price target on HCA Healthcare to $390 from $375 and keeps a Buy rating on the shares. The firm cites the company’s “upbeat” Q2 results featuring top and bottom-line beats and raised FY guidance driven by brisk volume trends complemented by strong margin performance, the analyst tells investors in a research note. Truist also notes the ongoing tailwinds from HCA’s “brisk” utilization environment, sees its underlying acuity trends as encouraging, and expects continued cost improvement and efficiency benefits.